Technical analyst Nitin Murarka of SMC Global is of the view that investors can buy Ranbaxy stock to achieve a target of Rs 475 in 2-3 trading sessions.

According to him, the investors will buy the stock with a strict stop loss of Rs 440.

Today, the shares of the company opened at Rs 450.90 on the Bombay Stock Exchange (BSE). The share price has seen a 52-week high of Rs 538 and a low of Rs 166.95 on BSE.

Current EPS of the stock is -11.18.

Ranbaxy Laboratories will appoint around 1,500 marketing executives, strengthening its sales group by around 50% in order to boost sales and get back its rank as the country's top drug manufacturer.

India chief executive officer Yugal Sikri will head the recruitment push.

Internationally, Ranbaxy, owned by Japan's Daiichi Sankyo, employs more than 12,000 people spread across 46 nations.

Ranbaxy Laboratories, in March 2010, announced that it will build up a protein on Pfenex's platform.

Under the conditions of the deal, Pfenex is eligible to obtain maintenance charges, milestone payments in addition to royalty payments on any product sales derived from the contract.

Ranbaxy and Pfenex researchers will team up on formulating the production strains and the route, which will be utilized to make product for clinical grwoth and commercial production of the biosimilar product.